Global microRNA expression and survival in patients with metastatic colorectal cancer in third-line treatment with cetuximab and irinotecan

被引：0
|
作者：
Schou, J. V.
Johansen, J. S.
Jensen, B. V.
Nielsen, D. L.
Kruhoffer, M.
机构：
[1] Herlev Hosp, Dept Oncol, DK-2730 Herlev, Denmark
[2] Univ Copenhagen, Herlev Hosp, Dept Oncol, Copenhagen, Denmark
[3] Univ Copenhagen, Herlev Hosp, Dept Oncol, DK-2730 Herlev, Denmark
[4] Herlev Univ Hosp, Dept Oncol, DK-2730 Herlev, Denmark
[5] Aarhus Hosp, Dept Clin Chem, Aarhus, Denmark
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.3602
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3602
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Optimizing Administration of Third-Line Treatment in Metastatic Colorectal Cancer
    Prager, Gerald W.
    Ducreux, Michel
    Argiles, Guillem
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (12) : 1 - 20
  • [22] THE PREDICTIVE AND PROGNOSTIC VALUE OF YKL-40 IN KRAS WILD TYPE PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH THIRD-LINE CETUXIMAB AND IRINOTECAN
    Spindler, K. L. S.
    Vittrup, B. V.
    Christensen, I. C.
    Schou, J. S.
    Jakobsen, A. J.
    Hogdall, E. H.
    Pallisgaard, N. P.
    Nielsen, D. N.
    Johannesen, H. J.
    Johansen, J. H.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : I39 - I39
  • [23] Cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan
    Pallisgaard, N.
    Spindler, K. G.
    Vogelius, I. S.
    Jakobsen, A. K. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
    Chong, G
    Dickson, JLB
    Cunningham, D
    Norman, AR
    Rao, S
    Hill, ME
    Price, TJ
    Oates, J
    Tebbutt, N
    [J]. BRITISH JOURNAL OF CANCER, 2005, 93 (05) : 510 - 514
  • [25] Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil
    Pfeiffer, P.
    Nielsen, D.
    Bjerregaard, J.
    Qvortrup, C.
    Yilmaz, M.
    Jensen, B.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (06) : 1141 - 1145
  • [26] Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
    G Chong
    J L B Dickson
    D Cunningham
    A R Norman
    S Rao
    M E Hill
    T J Price
    J Oates
    N Tebbutt
    [J]. British Journal of Cancer, 2005, 93 : 510 - 514
  • [27] Is there a third-line therapy for metastatic colorectal cancer?
    Grothey, Axel
    [J]. SEMINARS IN ONCOLOGY, 2006, 33 (06) : S36 - S38
  • [28] Third-Line Therapy in Metastatic Colorectal Cancer
    van de Haar, Joris
    Valeri, Nicola
    Voest, Emile E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (02): : 190 - 191
  • [29] Third-line therapy for metastatic colorectal cancer
    M. G. Gundgaard
    J. B. Soerensen
    E. Ehrnrooth
    [J]. Cancer Chemotherapy and Pharmacology, 2008, 61 : 1 - 13
  • [30] Third-line therapy for metastatic colorectal cancer
    Gundgaard, M. G.
    Soerensen, J. B.
    Ehrnrooth, E.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (01) : 1 - 13
12345